JnJ completes acquisition of Halda Therapeutics, its novel platform for cancer treatment Ruchika Sharma30 Dec 2025 1:48 PM ISTNew Brunswick: Johnson & Johnson has announced the successful completion of its acquisition of Halda Therapeutics OpCo, a clinical-stage...
JnJ discontinues mid stage study of skin disease drug Ruchika Sharma27 Dec 2025 3:30 PM ISTSpring House: Johnson & Johnson has discontinued a mid-stage trial of its experimental drug for moderate to severe atopic dermatitis after the...
JnJ Tremfya gets European Commission approval for children with plaque psoriasis Ruchika Sharma24 Dec 2025 10:00 AM ISTBelgium: Johnson & Johnson has announced that the European Commission has extended the marketing authorisation for TREMFYA (guselkumab)...
JnJ wins USFDA approval for subcutaneous Rybrevant Faspro for EGFR-Mutated NSCLC Ruchika Sharma20 Dec 2025 1:30 PM ISTHorsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT FASPRO (amivantamab and...
JnJ bags USFDA nod for Akeega plus prednisone for BRCA2 mutated metastatic castration sensitive prostate cancer Ruchika Sharma14 Dec 2025 3:00 PM ISTHorsham: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application...
JnJ Imaavy gets European Commission approval for generalised myasthenia gravis Ruchika Sharma3 Dec 2025 2:30 PM ISTBeerse: Johnson & Johnson has announced that the European Commission has approved a Marketing Authorisation for IMAAVY (nipocalimab), a...
JnJ to acquire Halda Therapeutics for USD 3.05 billion Ruchika Sharma18 Nov 2025 11:15 AM ISTNew Brunswick: Johnson & Johnson has announced that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a...
JnJ bags USFDA approval for Caplyta for major depressive disorder Ruchika Sharma9 Nov 2025 1:30 PM ISTTitusville: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CAPLYTA (lumateperone) as an...
JnJ Darzalex faspro approved by USFDA for high risk smoldering multiple myeloma Ruchika Sharma8 Nov 2025 12:36 PM ISTHorsham: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) has approved DARZALEX FASPRO (daratumumab and...
JnJ seeks USFDA nod for Stelara in treatment of pediatric ulcerative colitis Ruchika Sharma1 Nov 2025 2:01 PM ISTHorsham: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ gets USFDA priority review for Akeega plus prednisone for prostate cancer Ruchika Sharma17 Oct 2025 11:43 AM ISTHorsham: Johnson and Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company for its...
JnJ plans to separate Orthopaedics business Ruchika Sharma16 Oct 2025 1:52 PM ISTNew Brunswick: Johnson & Johnson has announced the Company's intent to separate its Orthopaedics business to enhance the strategic and...
